Business Context and Reporting Period
Company: AtriCure, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 13, 2020
Reporting Period: Event-based report regarding a specific corporate announcement on April 13, 2020.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a regulatory and clinical milestone. It does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial metric.
Material Changes
No material financial changes or operational shifts are reported in this document. The primary event is the acceptance of clinical trial results for presentation at a scientific conference.
Guidance, Outlook, and Management Commentary
- Clinical Milestone: AtriCure announced that results from its CONVERGE IDE (Investigational Device Exemption) trial have been accepted for presentation in the late-breaking abstract sessions at the Heart Rhythm Society (HRS) Scientific Sessions.
- Regulatory Status: The press release detailing these results is included as Exhibit 99.1.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the CONVERGE IDE trial results once the full abstract or presentation is released at the HRS Scientific Sessions.
- Review the full text of the press release (Exhibit 99.1) for details on the trial design and patient population.
- Monitor subsequent filings for any impact of these results on the FDA approval timeline for the device.
- Check the company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains none.